These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33387210)

  • 1. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?
    Ruberto F; Chistolini A; Curreli M; Frati G; Marullo AGM; Biondi-Zoccai G; Mancone M; Sciarretta S; Miraldi F; Alessandri F; Ceccarelli G; Barone F; Santoro C; Alvaro D; Pugliese F; Pulcinelli FM;
    J Thromb Thrombolysis; 2021 Jul; 52(1):105-110. PubMed ID: 33387210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.
    Matsui T; Hori A; Hamako J; Matsushita F; Ozeki Y; Sakurai Y; Hayakawa M; Matsumoto M; Fujimura Y
    J Thromb Haemost; 2017 Mar; 15(3):538-548. PubMed ID: 28071872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of von Willebrand factor-induced platelet agglutination by ADP does not result from reduced binding of total von Willebrand factor or its larger multimers.
    Zucker MB; Puszkin EG; Sussman II; Mauss EA
    J Lab Clin Med; 1990 Sep; 116(3):305-14. PubMed ID: 2401846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
    Patzke J; Favaloro EJ
    Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.
    De Marco L; Mazzuccato M; Grazia Del Ben M; Budde U; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1987 Aug; 80(2):475-82. PubMed ID: 3038958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL; Kupinski JM; Castella A; Ruggeri ZM
    J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
    Frontroth JP; Favaloro EJ
    Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
    De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
    Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.
    De Marco L; Girolami A; Russell S; Ruggeri ZM
    J Clin Invest; 1985 Apr; 75(4):1198-203. PubMed ID: 3157702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma.
    Casonato A; De Marco L; Mazzucato M; De Angelis V; De Roia D; Fabris F; Ruggeri ZM; Girolami A
    Blood; 1989 Nov; 74(6):2028-33. PubMed ID: 2804346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.
    LaDuca FM; Bettigole RE; Bell WR; Robson EB
    Blood; 1986 Oct; 68(4):927-37. PubMed ID: 3489493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets.
    Goto S; Salomon DR; Ikeda Y; Ruggeri ZM
    J Biol Chem; 1995 Oct; 270(40):23352-61. PubMed ID: 7559492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
    Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von willebrand factor domain-mediating botrocetin-induced binding to glycoprotein IB lies between Val449 and Lys728.
    Fujimura Y; Holland LZ; Ruggeri ZM; Zimmerman TS
    Blood; 1987 Oct; 70(4):985-8. PubMed ID: 3498523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding.
    Casonato A; Pontara E; Vertolli UP; Steffan A; Durante C; De Marco L; Sartorello F; Girolami A
    Clin Appl Thromb Hemost; 2001 Apr; 7(2):81-6. PubMed ID: 11292197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib.
    Girma JP; Fressinaud E; Christophe O; Rouault C; Obert B; Takahashi Y; Meyer D
    Thromb Haemost; 1992 Dec; 68(6):707-13. PubMed ID: 1287886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction.
    Yuan Y; Dopheide SM; Ivanidis C; Salem HH; Jackson SP
    J Biol Chem; 1997 Aug; 272(35):21847-54. PubMed ID: 9268316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.